NICE rejects Genzyme’s Caprelsa for medullary thyroid cancer
NICE has published draft guidelines rejecting Sanofi Genzyme’s Caprelsa for treating medullary thyroid cancer (MTC) that cannot be operated on or has spread around the body.
Read More
Tag: Genzyme
AstraZeneca, Genzyme named for ABPI code breaches
AstraZeneca and Genzyme have been named and shamed in advertisements for separate breaches of the Association of the British Pharmaceutical Industry’s Code of Practice.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
